HROW — Harrow Health, Inc.

Harrow (HROW) Q3 2025 Earnings Call Summary

1. Key Financial Results and Metrics

• Total Revenue: $71.6 million, a 45% increase year-over-year and a 12% sequential increase from Q2 2025.
• Year-to-Date Revenue: $183.2 million for the first nine months of 2025.
• Adjusted EBITDA: $22.7 million.
• GAAP Net Income: $1 million.
• Updated Full-Year Revenue Guidance: Revised to a range of $270 million to $280 million, reflecting a more conservative approach while still aiming for over $280 million.

2. Strategic Updates and Business Highlights

• Product Performance:

  • VEVYE: Generated $22.6 million in Q3, a 22% increase from Q2. Expected to finish the year strong with new formulary coverage starting January 2026, including a major pharmacy benefit manager (PBM) covering tens of millions of lives.
  • IHEEZO: Revenue of $21.9 million, up 20% from Q2, with strong demand expected to continue into Q4.
  • TRIESENCE: Revenue of $6.9 million, showing a 33% sequential increase. New leadership and strategies are in place to drive growth, particularly with its recent launch into the ocular inflammation market.
  • ImprimisRx: Generated $20.1 million in revenue, but facing potential impacts from a dispute with the California Board of Pharmacy and inventory shortages.

• Strategic Initiatives:

  • Acquisition of Melt Pharmaceuticals is underway, focusing on a non-opioid procedural sedation candidate, MELT-300.
  • Expansion of the Harrow Access for All program to improve patient access across the ophthalmic portfolio.
  • Plans for four new product launches over the next three years.

3. Forward Guidance and Outlook

• Q4 Expectations: Anticipated revenue of approximately $80 million, driven by strong performance from VEVYE and IHEEZO, with TRIESENCE expected to contribute positively.
• Long-Term Growth: Confidence in achieving sustained growth with a focus on expanding market share and improving coverage for VEVYE and IHEEZO.
• Seasonality Considerations: Anticipated typical seasonal decline from Q4 2025 to Q1 2026.

4. Bad News, Challenges, or Points of Concern

• ImprimisRx License Renewal: Ongoing discussions with the California Board of Pharmacy regarding license renewal, with uncertainty about the outcome.
• Inventory Shortages: Notable inventory shortages in October for ImprimisRx, potentially impacting Q4 revenue by $4 million to $6 million.
• Underperformance of TRIESENCE: Despite recent improvements, TRIESENCE has lagged earlier in the year, but new strategies are expected to drive future growth.

5. Notable Q&A Insights

• VEVYE Prescription Data: The company has shifted its reporting strategy to focus on revenue rather than third-party data, citing competitive reasons.
• ASP Dynamics: A modest decline in average selling price (ASP) for VEVYE was noted, with expectations for stabilization and potential increases due to improved coverage.
• Patient Transition Plans: The company is actively working on strategies to transition cash pay patients to covered prescriptions as new formulary changes take effect.
• Commercial Expansion: Plans to add 10 new sales territories for VEVYE, with a goal of reaching approximately 100 territories by mid-2026.

Overall, Harrow is positioned for continued growth with a strong product pipeline and strategic initiatives, despite facing some challenges in licensing and inventory management.